VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_12-vv-00629
Package ID: USCOURTS-cofc-1_12-vv-00629
Petitioner: L.A.
Filed: 2012-09-24
Decided: 2016-12-15
Vaccine: FluMist
Vaccination date: 2010-12-29
Condition: bilateral striatal necrosis (BSN)
Outcome: compensated
Award amount USD: 1419072.51

AI-assisted case summary:
On September 24, 2012, Magnus and Brandi Akerstrom filed a petition on behalf of their minor son, L.A., alleging that the FluMist vaccine administered on December 29, 2010, caused him to suffer seizures and encephalitis, with the litigated injury ultimately identified as bilateral striatal necrosis (BSN). Petitioners argued that L.A., who was five years old at the time, was concurrently fighting a pre-existing infectious illness, possibly Mycoplasma pneumoniae, and that the FluMist vaccine acted synergistically with this infection to trigger an immune-mediated process leading to BSN. L.A. was born on February 16, 2005. He appeared healthy in videos from December 25-26, 2010. On December 28, 2010, he developed symptoms of a viral illness, including headache, cough, stomachache, malaise, and fever. The following morning, December 29, he had a temperature of 101 degrees Fahrenheit. During a pediatric visit that afternoon, his temperature was normal, and the doctor noted his viral symptoms had resolved before administering FluMist. Over the next two days, L.A. experienced recurrent fever, profound sleepiness, and abdominal pain. On December 31, 2010, his eyes deviated left, he became unresponsive, and he had a tonic-clonic seizure lasting approximately 20-25 minutes, which was stopped by EMS with Valium. He was hospitalized from December 31, 2010, to February 2, 2011, with diagnoses including encephalitis of unknown etiology, hyperkinetic movement disorder, expressive aphasia, and motor ataxia. Approximately six weeks later, he was hospitalized again and discharged with diagnoses including BSN, positive Mycoplasma IgM and IgG, dystonia, dysarthria, aphasia, hyperkinetic movement disorder, and encephalopathy. Respondent opposed entitlement, initially arguing that none of L.A.'s treating doctors attributed BSN to FluMist and that petitioners lacked expert proof. Petitioners presented the report and testimony of Dr. Carlo Tornatore, a neurologist, who opined that BSN is immune-mediated, fits within the ADEM category, and can occur after an infectious or antigenic trigger. He suggested L.A.'s Mycoplasma titers might be false positives but stated that even if L.A. had Mycoplasma, FluMist could have augmented the immune response and acted as a substantial factor. He cited literature on influenza-related encephalopathy, BSN, cytokines, and blood-brain-barrier injury, noting L.A.'s prior FluMist exposure. Respondent's experts included pediatric neurologist Dr. Michael Kohrman, pediatric infectious disease specialist Dr. Hayley Gans, and pediatric immunologist Dr. Steven McGeady. Dr. Kohrman attributed the illness to a single infectious process, viewing Mycoplasma pneumoniae as sufficient and necessary, and noted the absence of case reports linking FluMist to BSN. Dr. Gans also attributed BSN to Mycoplasma, considered the one-to-two-day interval too rapid for FluMist, and stated FluMist could not cause influenza infection. Dr. McGeady opined that the rapid development of CNS lesions (40-48 hours post-vaccination) was too fast for a FluMist-driven immune mechanism and that the alleged synergy lacked laboratory support. Special Master Laura D. Millman granted entitlement on December 15, 2016, finding the case governed by Althen and Shyface principles. She credited Dr. Tornatore's synergistic immune theory, concluding that both FluMist and the pre-vaccine infection were substantial factors and that the two-day interval was medically appropriate for immune activation. She noted some treating physician support, such as Dr. Harry Abram's 2013 reference to vaccine-related encephalopathy. Following entitlement, damages were resolved by proffer. On December 6, 2019, Special Master Daniel T. Horner awarded $1,352,278.47 payable to L.A.'s guardians/conservators for L.A.'s benefit, comprising $1,047,884.72 for lost future earnings, $250,000.00 for pain and suffering, and $54,393.75 for first-year life care expenses. An additional $66,794.04 was awarded to Magnus and Brandi Akerstrom for past unreimbursable expenses. An annuity was also awarded for future life-care items, with specified growth rates for medical and non-medical expenses. Petitioners were represented by Clifford J. Shoemaker at entitlement and Renee Gentry at damages.

Theory of causation field:
Petitioners alleged that the FluMist vaccine administered on December 29, 2010, to L.A. (age 5.91, born Feb 16, 2005) caused seizures, encephalitis, and bilateral striatal necrosis (BSN). The theory of causation was that FluMist acted synergistically with a pre-existing infectious illness (possibly Mycoplasma pneumoniae) to trigger an immune-mediated process leading to BSN. Special Master Laura D. Millman granted entitlement on December 15, 2016, finding that FluMist, in combination with the co-existing infection, could synergistically affect the immune system, resulting in BSN. She concluded that FluMist had a synergistic effect with L.A.'s pre-existing infection, causing BSN, and that a two-day interval between vaccination and symptom onset was appropriate in this context. Petitioner's expert, Dr. Carlo Tornatore, supported this synergistic immune theory. Respondent's experts, Dr. Michael Kohrman, Dr. Hayley Gans, and Dr. Steven McGeady, argued that the BSN was caused solely by the pre-existing infection, primarily Mycoplasma pneumoniae, and that the onset was too rapid for a FluMist-induced reaction. Damages were resolved by proffer on December 6, 2019, by Special Master Daniel T. Horner, who awarded a total of $1,419,072.51 ($1,352,278.47 lump sum for L.A. plus $66,794.04 to parents) plus an annuity for future life care. Petitioners' counsel at entitlement was Clifford J. Shoemaker, and at damages was Renee Gentry. Respondent's counsel was Glenn A. MacLeod.

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_12-vv-00629-1
Date issued/filed: 2017-01-09
Pages: 22
Docket text: PUBLIC DECISION (Originally filed: 12/15/2016) regarding 97 Ruling on Entitlement Signed by Special Master Laura D Millman. (tlf) Copy to parties.
--------------------------------------------------------------------------------
Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 1 of 22
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 12-629V
December 15, 2016
Not to be Published
***************************************
L.A., a minor, by his parents and natural *
guardians, MAGNUS and BRANDI *
AKERSTROM, *
*
Petitioners, *
* FluMist; bilateral striatal necrosis (“BSN”);
v. * pre-existing Mycoplasma pneumonaie;
* substantial factors in causing BSN
SECRETARY OF HEALTH *
AND HUMAN SERVICES, *
*
Respondent. *
***************************************
Clifford J. Shoemaker, Vienna, VA, for petitioners.
Glenn A. MacLeod, Washington, DC, for respondent.
MILLMAN, Special Master
RULING ON ENTITLEMENT1
On September 24, 2012, petitioners filed a petition under the National Childhood
Vaccine Injury Act, 42 U.S.C. § 300aa-10-34 (2012), alleging that FluMist, which their son L.A.
received on December 29, 2010, caused him seizures and encephalitis. Pet. at ¶¶ 8-10. Two
days after receiving FluMist, L.A. had a seizure. Id. at ¶ 9.
1 Because this unpublished decision contains a reasoned explanation for the special master’s action in this
case, the special master intends to post this unpublished decision on the United States Court of Federal
Claims’ website, in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 note (2012)
(Federal Management and Promotion of Electronic Government Services). Vaccine Rule 18(b) states that
all decisions of the special masters will be made available to the public unless they contain trade secrets
or commercial or financial information that is privileged and confidential, or medical or similar
information whose disclosure would constitute a clearly unwarranted invasion of privacy. When such a
decision is filed, petitioner has 14 days to identify and move to redact such information prior to the
document’s disclosure. If the special master, upon review, agrees that the identified material fits within
the banned categories listed above, the special master shall redact such material from public access.

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 2 of 22
On September 24, 2012, this case was assigned to former Special Master Daria Zane.
On October 17, 2012, the case was reassigned to the undersigned.
On October 18, 2012, petitioners moved for subpoena authority to obtain medical
records, which the undersigned granted.
On January 4, 2013, petitioners filed their first set of medical records.
During the first telephonic status conference on January 23, 2013, the undersigned
discussed settlement with counsel. As reflected in the undersigned’s Order dated January 23,
2013, L.A. had a viral illness prior to his receipt of FluMist. On the morning of his later receipt
of FluMist, L.A. had a fever of 101 degrees. In the afternoon, when he presented at Acute Care,
he had a normal temperature and the pediatrician noted L.A.’s symptoms of a viral illness had
resolved. L.A. received FluMist. He was very tired afterward and had a fever over the next
three days. Two days after vaccination, L.A. had a tonic-clonic seizure lasting 20-25 minutes.
He was in the hospital for over a month. His discharge diagnoses were encephalitis of unknown
etiology, hyperkinetic movement disorder, expressive aphasia, and motor ataxia secondary to
encephalitis of unknown etiology. Med. recs. Ex. 2, at 144. L.A. was again hospitalized a
month and one-half later. He was discharged with the diagnoses of bilateral striatal necrosis
(“BSN”), positive Mycoplasma2 IgM and IgG, dystonia, hyperkinetic movement disorder,
dysarthria, aphasia, and encephalopathy. Id. at 151.
The undersigned stated in her Order dated January 23, 2013 that L.A. was improving
from the fever, cough, headache, stomachache, and malaise that the pre-vaccination infection
caused him the day before he took the FluMist vaccine, although he still had a fever of 101
degrees in the morning, hours before he received FluMist vaccine. However, his symptoms
worsened after he received FluMist. Order at 1. The undersigned informed counsel at the status
conference and reiterated in her Order following the status conference that she had previously
ruled for petitioners in similar cases, based on the Federal Circuit’s decision in Shyface v. Sec’y
of HHS, 165 F.3d 1344, 1345, 1347,1352-53 (Fed. Cir. 1999) (whole-cell DPT vaccine and E.
coli infection both caused high fever in baby vaccinee who subsequently died; both the vaccine
and the infection were equal substantial factors in the baby’s vaccine injury and death; a vaccine
need not be the predominant substantial factor in order for petitioners to prevail). The two cases
of the undersigned which she mentioned at the status conference and listed in her Order as
consistent with the Federal Circuit’s decision in Shyface were Nash ex rel. Nash v. Secretary of
Health and Human Services, No. 00-149V, 2002 WL 1906501 (Fed. Cl. Spec. Mstr. June 27,
2 Mycoplasma is “a genus of bacteria….” Dorland’s Illustrated Medical Dictionary 1216 (32d
ed. 2012). Hereinafter, Dorland’s. Mycoplasma pneumoniae is “a species that often causes
inapparent infections or mild respiratory tract disease but can also cause mycoplasmal
pneumonia….” Id. at 1217.
2

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 3 of 22
2002) (pneumococcal infection and fever preceded whole cell DPT vaccination, followed by
increased fever and pneumococcal meningitis), and Herkert ex rel. Herkert v. Secretary of Health
and Human Services, No. 97-518V, 2000 WL 141263 (Fed. Cl. Spec. Mstr. Jan. 19, 2000)
(cytomegalovirus which infant had been fighting off preceded acellular DPT vaccination,
followed by transverse myelitis one day post-vaccination). At the status conference,
respondent’s counsel stated he would accept a reasonable demand, although he had not yet
received feedback from his client.
Petitioners’ counsel made repeated motions for extensions of time to make a demand in
order to obtain more medical records. It took a considerable amount of time for petitioners to
finish a life care plan. On August 12, 2013, petitioners made a demand on respondent.
On September 9, 2013, the undersigned held a status conference, during which
respondent’s counsel said that HHS was actively considering petitioners’ demand.
On October 21, 2013, the undersigned held a status conference, during which
respondent’s counsel stated he would respond to petitioners’ demand with a counteroffer on
either October 28, 2013 or October 29, 2013.
On October 30, 2013, the undersigned held a status conference, during which
respondent’s counsel said that HHS wanted to suspend negotiating a settlement until petitioners
filed an expert report.
On December 2, 2013, respondent filed her Rule 4(c) Report, stating petitioners should
not prevail because petitioners had not filed an expert report and none of L.A.’s treating doctors
attributed his BSN to FluMist. Resp’t’s Rep. at 8, 10.
On December 3, 2013, the undersigned held a status conference, during which
petitioners’ counsel requested until February 28, 2014 to file petitioners’ expert report.
Petitioners subsequently moved three times for extensions of time to file their expert
report.
On July 14, 2014, petitioners filed the expert report of Dr. Carlo Tornatore, Professor
and Vice Chairman of the Department of Neurology at Georgetown University Hospital and
Director of the hospital’s Multiple Sclerosis and Associated Autoimmune Disorders Center. Ex.
46. He wrote that FluMist is an attenuated live-virus vaccine containing two influenza A strains,
including H N , and one influenza B strain. Id. at 7. He thought L.A.’s titer results for IgM and
1 1
IgG of Mycoplasma pneumoniae were false positives. Id. at 8. He stated the onset of neurologic
symptoms (the seizure) two days after vaccination was an appropriate interval for a post-
infectious immune response to the FluMist vaccine, particularly since L.A. had received the
same viral strains in his two previous FluMist vaccinations two months apart in 2009 (one
containing just H N and the other the remaining seasonal strains). Id. at 8-9.
1 1
3

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 4 of 22
Attached to Dr. Tornatore’s report are six articles, the first of which is a case report
entitled Influenza B Acute Necrotizing Encephalopathy: A Case Report and Literature Review,
by M. Sazgar, et al., 28 Pediatr. Neurol. 396-99 (2003). The case report’s authors wanted to
increase awareness of influenza virus as a cause of acute encephalopathy and of acute
necrotizing encephalopathy in western countries because there were only two cases reports each
from the United Kingdom, Spain, and the United States. Id. at 396. The girl in the case report
was nine years old with a one-day history of fever and sore throat. Id. Her doctor diagnosed her
with tonsillitis and prescribed oral antibiotics. The next day, she developed fever, headache,
vomiting, and diarrhea. Her local hospital admitted her and the doctors treated her with
rehydration and acetaminophen. She became lethargic and shaky. Three days later, because of
her persistent symptoms, the girl’s local hospital transferred her to a university hospital where
she had a generalized tonic-clonic seizure lasting several minutes. CT scan revealed bilateral
symmetric basal ganglia hypodensities and brain edema. Her EEG showed diffuse slowing. The
girl had not received an influenza immunization. Her six-year-old sister had also manifested
fever and flu-like symptoms. Id. The hospitalized girl was negative for Mycoplasma
pneumoniae IgM. Id. at 397. She underwent plasmapheresis. Unfortunately, her brain necrosis
progressed and, on the fourth day of her intensive care unit admission, she died. Id.
Neuropathology revealed multiple regions of bilateral acute necrosis involving the posterior two-
thirds of the body of the putamen, hippocampal formation, collicular plate of the midbrain, and
thalami. There were also areas of punctate hemorrhages within these lesions. The girl also had
evidence of bilateral bronchopneumonia and early acute tubular necrosis. Id. In their discussion
of this case, Sazgar et al. state, “The most common virus associated with acute necrotizing
encephalopathy is influenza A ….” Id. Influenza B grew from a nasopharyngeal swab of the
girl’s nasal passages or nares, which confirmed a recent infection with influenza B virus, but did
not prove a causal relationship because the doctors did not perform polymerase chain reaction
(“PCR”) testing of her cerebrospinal fluid (“CSF”) for influenza B or other associated viral
DNA. Id. at 398.
Sazgar et al. note that acute necrotizing encephalopathy predominantly appears in the
medical literature from Japan and Taiwan. Id. at 397. Its clinical presentation is “a rapidly
deteriorating illness manifesting as fever and upper respiratory or gastrointestinal symptoms
followed by seizures and coma. The pathologic hallmark of this condition is multifocal,
symmetric brain lesions . . . . Gray and white matter are involved.” Id.3
Sazgar et al. discuss the pathogenesis of influenza-associated encephalopathy and
specifically acute necrotizing encephalopathy. Id. at 399. They posit that an immune-mediated
3 Of note, L.A.’s pre-vaccination infection, involving fever, cough, headache, stomachache, and
malaise, appeared to be resolving, although he still had 101 degrees of fever the morning of the
vaccination, with a normal temperature at the Acute Care facility in the afternoon. After the vaccination,
his fevers resumed, with somnolence, exhaustion, and abdominal pain. The FluMist L.A. received in
2010 contained two influenza A attenuated viruses and one influenza B attenuated virus.
4

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 5 of 22
mechanism may be the pathogenesis of this illness. In support of this theory, Sazgar et al. cite
Sugaya’s recent study in which doctors detected viral DNA for HHV-6 and HHV-7 in the CSF of
four of eight patients with influenza-associated encephalopathy, suggesting to Sugaya, et al. that
influenza virus may have reactivated the latent HHV-6 or HHV-7 in these patients’ brains,
causing encephalopathy or febrile seizures. Id. Sugaya et al. note that HHV-6 and HHV-7
induce numerous cytokines, such as interferon and tumor necrosis factor, and a dual infection of
these viruses with influenza virus may enhance cytokine induction. Citing another Sugaya study,
Sazgar et al. state that cytokine-induced neurotoxicity and the subsequent breakdown of the
blood-brain barrier may contribute to inducing acute necrotizing encephalopathy. Id.
The second attachment to Dr. Tornatore’s expert report is a Letter to the Editor, entitled
Must Acute Necrotizing Encephalopathy of Childhood and Acute Bilateral Striatal Necrosis Be
Differentiated? by H-S Wang, 30 Pediatr. Neurol. 4:299-300 (2004). Dr. Wang, a pediatric
neurologist in Taiwan, states the Sazgar et al. article about the nine-year-old girl who died of
acute necrotizing encephalopathy of childhood (“ANEC”) due to influenza B virus was of great
interest. Id. at 299. Wang discusses BSN, mentioning three causes, the last of which is acute
disease due to a para-infectious or post-infectious setting. Id. at 300. In this group, he says acute
bilateral striatal necrosis (“ABSN”), characterized by dystonic movement disorder and basal
ganglia imaging abnormalities, manifests often after an upper respiratory tract infection,
although doctors have not identified a specific microorganism. Id. Doctors have identified
measles, Mycoplasma pneumoniae, and beta-hemolytic streptococci as possible causes since the
early 1990s. Wang writes that BSN may have a similar clinical manifestation as acute
encephalopathy as ANEC, viral precipitation, and perhaps cytokine storm in pathogenesis. Id.
Dr. D.B. Sinclair, one of the co-authors of the Sazgar article, responded to Dr. Wang’s
letter. Dr. Sinclair states that Dr. Wang’s BSN case differs from Sazgar’s acute necrotizing
encephalopathy (“ANE”) case in that BSN involves dystonia, post-infectious timing, and white
matter involvement. The post-infectious time course and white matter changes in Dr. Wang’s
case suggest a post-infectious autoimmune disease like acute disseminating encephalomyelitis
(“ADEM”) rather than an acute inflammatory disease such as ANE. Id.
The fourth attachment to Dr. Tornatore’s expert report is entitled Acute Neurological
Dysfunction Associated with Destructive Lesions of the Basal Ganglia in Children, by F.
Goutières and J. Aicardi, 12 Ann Neurol 328-32 (1982). The authors discuss the cases of three
infants who had an infection and subsequent BSN. The first case involved a one-year-old boy
who had a febrile illness with vomiting, diagnosed as pharyngitis. Two days later, he became
obtunded, with stiffness of all four limbs, and was hospitalized with a fever. Months later, he
died after a hip operation. Pathology was performed on his brain, but not on the other two
patients described in the article since they survived. Id. at 328. Goutières and Aicardi identify
three types of BSN, the third of which presents with abrupt neurological dysfunction following
an acute systemic illness. Id. at 331. The three patients the authors discuss in this article fall
within this third group. Goutières and Aicardi state the temporal relationship between an acute
5

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 6 of 22
febrile illness and the onset of neurological signs is consistent with a para-infectious
encephalitis.4
The fifth attachment to Dr. Tornatore’s expert report is entitled Neurological
Manifestations of Influenza Infection in Children and Adults: Results of a National British
Surveillance Study, by A. Goenka, et al., 58 Clin. Infec. Dis 6:775-84 (2014). The authors note
that influenza A (H N ) in 2009 led to an increase in reports of neurological manifestations. Id.
1 1
at 776. They surveyed the United Kingdom nationally to find neurological manifestations of
influenza and found four adults and 21 children to study. Id. None of the Goenka subjects had
received flu vaccine. Id. at 783. There were four cases of acute necrotizing encephalopathy
(“ANE”). Id. at 776. All patients had fever and/or respiratory symptoms. Id. Influenza A was
detected by PCR in 84 percent of patients, of whom 95 percent had the H N subtype. Influenza
1 1
B was detected in 16 percent of patients. Id. One child and one adult had co-infections with
streptococcus pneumoniae, the first with pneumococcal meningitis, and the second with
pneumococcal sepsis. Id. at 776, 779. One of the ANE patients, a two-year-old boy, had a two-
day history of pyrexia, diarrhea, and vomiting. Unfortunately, he died. Id. at 780. The authors
state the most commonly associated pathogen with ANE is influenza. Id. at 781. The authors
describe two broad categories of influenza-like illness followed by neurological manifestations,
the first of which is acute, in association with an innate immune response and a cytokine storm.
Id. at 782. Doctors have found increased concentrations of pro-inflammatory cytokines in the
serum and CSF of children with neurological manifestations of influenza. Id. Two patients had
co-infection with streptococcus pneumonia and died. Pneumococcal/influenza respiratory co-
infection is a recognized distinct clinical entity associated with poor outcome. Id. They state,
“While the pathophysiology underlying the synergy between the two organisms is poorly
understood, proposed factors include the role of influenza virulence factors in epithelial damage
and subsequent facilitated entry of pneumococcus, as well as upregulation of the inflammatory
response.” Id.5
The sixth attachment to Dr. Tornatore’s expert report is entitled Acute Encephalopathy
with Bilateral Striatal Necrosis. A Distinctive Clinicopathological Condition, by S. Rosemberg,
et al., 23 Neuroped 310-15 (1992). The authors describe two distinct clinical entities, the second
of which has an acute onset, which nearly always follows an infectious disease, and consists of
disturbance of consciousness, seizures, postural troubles, dystonia, and tremors. Id. 310. They
describe two cases and remark that the main characteristics of the children’s neurological
syndrome were acute onset with depression of consciousness, muscular rigidity, tremor of the
upper extremities, and dystonic movements of the hands. Id. at 312. The children’s symptoms
4 Of note, the first patient’s onset of neurological symptoms was two days after his febrile illness.
In L.A.’s case, his seizure occurred two days after he had a fever of 101 degrees in the morning and
FluMist vaccine in the afternoon.
5 Of note, in Dr. Tornatore’s subsequent expert reports and his testimony, he describes as
“synergy” or “synergistic” the effect of L.A.’s FluMist on his pre-existing infection in causing L.A.’s
BSN.
6

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 7 of 22
began a few days following an upper respiratory tract infection associated with tonsillitis in one
case, and with diarrhea in the other case. Id. The authors analyze 13 cases of BSN, all following
an infectious illness like upper respiratory tract infection (9 cases), mumps (2 cases),
Mycoplasma pneumoniae (1 case), and acute otitis media (1 case). Id. They state, “The
beginning of neurologic disease was always abrupt with disturbance of consciousness ranging
from lethargy to coma.” Id.
On July 18, 2014, the undersigned held a status conference, during which respondent’s
counsel said he sent petitioners’ expert Dr. Tornatore’s report to HHS and wanted 60 days to file
respondent’s expert report, due September 16, 2014. Petitioners’ counsel stated that respondent
made a counteroffer to petitioners’ demand.
Respondent subsequently made numerous motions for an extension of time to file
respondent’s expert report. Petitioners filed more medical records.
On October 31, 2014, respondent filed the expert reports of Dr. Michael H. Kohrman, a
pediatric neurologist, and Dr. Hayley Altman Gans, a pediatric infectious disease specialist. Exs.
A, C. Dr. Kohrman states, that L.A.’s illness began with headache, fever, and stomachache on
December 28, 2010 following exposure to a sick family member. Ex. A, at 9. He states that
L.A.’s clinical symptoms, which began before FluMist vaccination, persisted after FluMist
vaccination and intensified. Id. L.A.’s positive IgM and IgG serology to Mycoplasma
pneumoniae during this acute phase means L.A. had an acute infection with Mycoplasma
pneumoniae. Id. Dr. Kohrman does not believe FluMist caused L.A.’s BSN because there are
no case reports of FluMist associated with BSN or acute necrotizing encephalopathy of
childhood. Id. at 10. Dr. Kohrman believes L.A. had a single infectious process prior to his
FluMist vaccination consisting of cough, fever, and stomachache, which continued over the next
three days and progressively became more symptomatic. (L.A.’s pediatrician noted on
December 29, 2010 that L.A.’s viral syndrome, manifesting as fever, cough, headache,
stomachache, and malaise, resolved before L.A. received FluMist. Med. recs. Ex. 1, at 19.) Dr.
Kohrman cites Dr. Abram, L.A.’s treating pediatric neurologist, who entertained a strong
suspicion that Mycoplasma pneumoniae caused L.A.’s BSN. Ex. A, at 10. Attached to Dr.
Kohrman’s expert report are six articles associating Mycoplasma pneumoniae with BSN or a
similar encephalopathy. Tabs 4-9, attached to Ex. A.
Dr. Gans states there are no reports in the medical literature associating FluMist with
BSN. Ex. C, at 5-6, 7. She asserts that Mycoplasma pneumoniae caused L.A.’s cough. Id. at 6.
She says L.A.’s post-vaccinal fever and progressive neurologic symptoms are consistent with a
post-infectious inflammatory illness. Id. She notes that neurological progression was rapid. Id.
She also notes that L.A. did not have mycoplasmal pneumonia but did have upper airway
disease. Id. Dr. Gans thinks L.A.’s neurologic symptoms began one day after receiving FluMist
because of his increased sleepiness. Id. at 7. She thinks one and two days (his seizure was two
days post-FluMist) are a very rapid onset for an autoimmune process, making FluMist’s role in
causing L.A.’s BSN improbable. Id. Dr. Gans further states that FluMist, an attenuated viral
7

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 8 of 22
vaccine, cannot cause an influenza infection or illness. Id. at 8. She attributes L.A.’s BSN to
Mycoplasma pneumoniae. Id. Attached to Dr. Gans’s expert report are three articles relating
Mycoplasma pneumoniae to neurologic problems, plus other articles on influenza and infections.
On November 5, 2014, the undersigned held a status conference, during which
petitioners’ counsel said being on a dual track, i.e., attempting to settle the case and preparing for
a hearing, was fine. The undersigned asked him to obtain a supplemental expert report from Dr.
Tornatore responding to respondent’s experts’ Dr. Kohrman’s and Dr. Gans’s reports.
Petitioners’ counsel wanted 90 days or until February 11, 2015 to file Dr. Tornatore’s
supplemental expert report. Respondent’s counsel stated that settlement was not dead, but he
wanted to continue on the litigative track.
Petitioners filed more medical records and moved twice for extensions of time to file Dr.
Tornatore’s supplemental expert report.
On May 11, 2015, petitioners filed Dr. Tornatore’s supplemental expert report. Ex. 53.
He states that he noted in his initial report that both Mycoplasma and influenza infections can
cause BSN as a post-infectious autoimmune phenomenon. Ex. 53, at 1. He thinks it is
biologically plausible for FluMist, which contains attenuated live-virus vaccines, to recapitulate
an autoimmune cascade similar to wild influenza virus since both the wild virus and FluMist
share antigenic homology. Id. Even accepting that L.A.’s pre-vaccinal infection was
Mycoplasma pneumoniae, Dr. Tornatore states that L.A. had a concurrent infection with
attenuated influenza viral strains, which stimulated an immune response to these viral antigens.
Id. at 2. He states that BSN is a result of an aberrant autoimmune response to viral and bacterial
antigens. If both Mycoplasma antigens and influenza antigens were present concurrently in L.A.,
Dr. Tornatore states it was biologically plausible that a synergistic immune response occurred,
with the FluMist further stimulating the aberrant response. Id. Dr. Tornatore mentioned he had
six years of training in virology as a post-doctoral fellow, during which he analyzed questions
similar to those involved in this case dealing with the interface among the nervous system, the
immune system, and viruses. Id.
On May 18, 2015, the undersigned held a status conference, during which respondent’s
counsel said he would send Dr. Tornatore’s supplemental expert report to HHS. Respondent’s
counsel recognized this case involves a Shyface issue.
On June 19, 2015, the undersigned held a status conference, during which respondent’s
counsel said HHS had read Dr. Tornatore’s supplemental expert report and was consulting with a
pediatric immunologist. L.A.’s condition required extensive money. HHS wanted to file a
report from this pediatric immunologist, Dr. Steven McGeady. The deadline was August 21,
2015.
Respondent made motions for an extension of time to file Dr. McGeady’s expert report.
8

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 9 of 22
On September 24, 2015, respondent filed the expert report of Dr. Steven J. McGeady, a
pediatric immunologist now practicing as a pediatrician specializing in allergy. Ex. E1.
(Respondent subsequently filed a corrected expert report from Dr. McGeady as Exhibit G.) Dr.
McGeady writes that L.A. had an intercurrent viral illness before receiving FluMist. After
receiving FluMist, L.A.’s parents noted he was excessively somnolent and then L.A. had a
seizure. Ex. E1, at 3. Dr. McGeady’s opinion is that Mycoplasma pneumoniae was more likely
than the FluMist vaccine to have caused L.A.’s BSN. Id. at 4. L.A. had a headache on
December 28, 2010, followed the next morning by a fever of 101 degrees. Id. Because L.A.’s
father and brother had been sick, an illness or illnesses were present in the family at that time.
Id. At the pediatrician’s office in the afternoon of December 29, 2010, L.A. seemed to be well
and he was afebrile. He received FluMist. Over the next 48 hours, L.A. continued to be unwell
and had considerable somnolence and intermittent fever. “This sequence suggests a continuous
illness with onset of symptoms on 12/28/2010, ensuing fever and worsening lethargy over the
next several days, leading to a seizure on 12/31/2010.” Id. at 4-5. Dr. McGeady states that a
head CT scan revealed a fully developed central nervous system lesion only 48 hours after
FluMist vaccination. Dr. McGeady thinks this is too rapid an onset for FluMist to be causative.
Id. at 5. Dr. McGeady states L.A.’s fever preceded the FluMist and then, subsequently, L.A.
continued to have fever and somnolence. Dr. McGeady opines that no physiologic mechanism
could explain such a rapid response after FluMist. Id. Dr. McGeady states there is no medical
literature attributing BSN to FluMist received 48 hours earlier. Id. at 8.
Also on September 24, 2015, respondent filed Dr. McGeady’s supplemental expert
report in response to Dr. Tornatore’s expert report (Ex. 53). Ex. E2. Dr. McGeady says Dr.
Tornatore’s opinion is inconsistent with L.A.’s clinical history of febrile illness and extreme
somnolence both before and immediately after his receipt of FluMist on December 29, 2010. Id.
at 1-2. Dr. McGeady states the presence of profound somnolence on December 29 and 30, 2010
and L.A.’s pre-vaccinal fever the morning of December 29, 2010 “argue strongly against the role
of an immune reaction” to FluMist because such a reaction, even if it were anamnestic, would
require several days to become manifest. Id. at 2. Dr. McGeady writes that even if L.A. retained
T-memory cells from prior FluMist vaccinations in 2009, the detection of fully developed
cerebral lesions 40 hours after FluMist vaccination is too soon for FluMist to be causal. Id. Dr.
McGeady thinks Dr. Tornatore’s theory that FluMist may have produced a synergistic immune
reaction with Mycoplasma infection is highly speculative and devoid of supportive laboratory
evidence. Id. at 3. Dr. McGeady says he does not know of any laboratory tests that could
demonstrate “synergy between the independent immune reactions” to Mycoplasma and FluMist,
nor does medical literature describe such phenomena apart from describing the use of adjuvants
to enhance a body’s immune response to an antigen. Id. Dr. McGeady states L.A.’s “response to
the FluMist is conflated with the evolving picture of his encephalitis and bilateral striatal
necrosis. It is not possible to separate the clinical features, if any, of his response to the FluMist,
but there is no clinical evidence of any sort of aberrant response to this vaccine.” Id. Dr.
McGeady expounds upon FluMist’s localization to the nares as proof that no one taking FluMist
could have a systemic, including an inflammatory, response to it. Id. at 3-4.
9

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 10 of 22
On October 16, 2015, the undersigned held a status conference, during which
petitioners’ counsel requested a deadline of November 30, 2015 to file Dr. Tornatore’s response
to respondent’s expert Dr. McGeady’s reports (Exs. E1 and E2). The undersigned discussed
again (and included in an Order she issued the same date) her prior decisions in Nash and
Herkert and cited additional decisions the undersigned wrote consistent with the Federal
Circuit’s opinion in Shyface See Mouille v. Sec’y of HHS, No. 05-1204V, 2009 WL 4456207
(Fed. Cl. Spec. Mstr. Nov. 17, 2009) (upper respiratory infection and flu vaccine led to
encephalitis); Pearson v. Sec’y of HHS, No. 03-2751V, 2008 WL 5093378 (Fed. Cl. Spec. Mstr.
Nov. 6, 2008) (upper respiratory infection and hepatitis B vaccine led to transverse myelitis); and
Camerlin v. Sec’y of HHS, No. 99-615V, 2003 WL 22853070 (Fed. Cl. Spec. Mstr. Oct. 29,
2003) (otitis media and haemophilus B influenza vaccine led to either transverse myelitis or
ADEM). Respondent’s counsel said he would communicate the undersigned’s views to HHS.
On November 30, 2015, petitioners filed Dr. Tornatore’s second supplemental report
responding to Dr. McGeady’s supplemental expert report. Ex. 54. Dr. Tornatore recounts the
findings of two reports, indicating that Mycoplasma pneumoniae can increase production of
interleukin-6 and interleukin-8, and FluMist can also increase production of interleukin-8, a
cytokine that is a potential factor in causing BSN. Id. at 1-2. Dr. Tornatore comments, “Good
clinical practice has dictated that vaccination during an acute infection is not wise given the
concern that an aberrant synergistic response could occur between the vaccine and the organism
causing the infection.” Id. at 2.
The paper to which Dr. Tornatore referred discussing detection of interleukins-6 and -8
in serum and CSF in the context of BSN lesions after Mycoplasma pneumoniae infection is
entitled, Case Report. Reversible bilateral striatal lesions following Mycoplasma pneumoniae
infection associated with elevated levels of interleukins 6 and 8, Z-F Yuan, et al., 38 Brain and
Development 149-53 (2016). Ex. 57. (The version petitioners filed as Exhibit 57 does not have
the page numbers that the journal included in its 2016 publication, i.e., pages 149-53. Since the
2016 publication is not in evidence, the undersigned will refer to the page numbers in Ex. 57
available in 2015, i.e., pages 1-5.) The authors state that Mycoplasma pneumoniae is a common
cause of respiratory tract infection in children. Ex. 57, at 1. One of the most common
manifestations outside the lungs is central nervous system (“CNS”) dysfunction, including inter
alia encephalitis or meningoencephalitis, ADEM, and a few cases of BSN. Id. The authors also
state that the precise pathogenic mechanism by which Mycoplasma pneumoniae causes
neurological disorders remains unknown. Id. Earlier studies reveal that inflammatory cytokines
such as interleukin-6 (“IL-6”) and interleukin-8 (“IL-8”) are involved in the development of
CNS symptoms that Mycoplasma pneumoniae causes. Id. at 1-2. Three mechanisms have been
proposed to explain the pathogenesis of CNS symptoms due to Mycoplasma pneumoniae: (1)
cytokine production (direct type); (2) autoimmune-mediated mechanisms (indirect type); and (3)
vascular occlusion. Id. at 4. Other scientists posit a role for increased IL-6 and IL-8 in the
inflammatory processes leading to CNS dysfunction. Id. Yuan et al. notice in this child’s case
that her IL-8 increased significantly in her CSF. Id. After doctors successfully treated the girl’s
BSN, her levels of IL-6 and IL-8 reduced markedly. Id. By one month, they had returned to
10

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 11 of 22
normal in her serum. Id. To Yuan et al., these results suggest that IL-6 and IL-8 play important
roles in the pathogenesis of BSN. Id. Another author posited that an underlying mechanism for
BSN might be local vascular injury mediated by cytokines and chemokines induced by
Mycoplasma pneumoniae. Id. Using this analysis, Yuan et al. posit that elevated levels of IL-6
and IL-8 may cause regional endovasculitis, which further induces focal vascular occlusion,
finally causing a bilateral striatal lesion. Id. Yuan et al. include Table 1, which depicts 12
reported cases in the medical literature of reversible striatal lesions associated with Mycoplasma
pneumoniae infection. Id. at 3. In the seventh case, there was a one-day onset between the
respiratory symptoms to the CNS symptoms of Parkinsonism and dystonia in an eight-year-old
male. Id. In the eleventh case, there was a two-day onset between the respiratory symptoms and
encephalopathy and dystonia in a five-year-old male. Id.
The paper to which Dr. Tornatore referred in his second supplemental report is entitled,
Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults by M.I.
Barria, et al., 207 J Infec Dis 115-24 (2013). Ex. 55. Live attenuated influenza vaccine
(“LAIV”) produced enhancement in serum antibody response in 24 percent of subjects. Id. at 7.
On December 16, 2015, the undersigned held a status conference, during which
respondent’s counsel stated petitioners were not motivated to settle because respondent could not
get them to agree to a litigative risk discount in damages in light of the undersigned’s prior
discussions with counsel. Respondent’s counsel did not know if HHS would let him settle. The
undersigned directed counsel to speak to their clients to see if they would settle.
On December 5, 2016, petitioners filed their joint affidavit. Ex. 60.
On December 7, 2016, this case went to hearing.
FACTS
L.A. was born on February 16, 2005.
On December 29, 2010, L.A. went to Acute Care, complaining of having had a cough,
headache, stomachache, and malaise. Med. recs. Ex. 1, at 19. His sibling had otitis media,
which resolved. L.A.’s temperature in the Acute Care office was 98.1 degrees. The doctor’s
diagnosis was that his viral syndrome resolved and L.A. received FluMist.
L.A. continued to have fever the next two days between 101 and 101.5 degrees with
periods of excess sleepiness. Med. recs. Ex. 18, at 5. On December 31, 2010, Jacksonville
Fire/Rescue reported that L.A. had a grand mal seizure lasting about 20 minutes. His skin
temperature was warm. His mother stated the child had had a fever for three days. Med. recs.
Ex. 3, at 2.
11

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 12 of 22
On December 31, 2010, at 12:23 p.m., L.A. went to Baptist Medical Center and Wolfson
Children’s Hospital with a temperature of 101.3 degrees. Med. recs. Ex. 3, at 140. He was
diagnosed with complex febrile seizure and meningitis. Also on December 31, 2010, L.A. saw
Dr. Deborah C. Abram, a pediatrician, who wrote that on Tuesday evening, December 28, 2010,
L.A. had a headache. Med. recs. Ex. 18, at 3. On Wednesday morning, December 29, 2010,
L.A. woke with a temperature of 101 degrees. His mother took him to Primary Care where the
physician examined L.A. and told the mother that L.A. did not have strep or the flu, looked good,
had had a viral illness, and gave L.A. FluMist, sending him home. L.A.’s fevers continued over
the next two days. He was very sleepy, and fell asleep at the dinner table. His mother said he
had slept for four hours in the middle of the living room. He was exhausted with temperatures in
the 101 to 101.5 degree range. He did not have vomiting or diarrhea. On the morning of
admission, December 31, 2010, L.A. woke at 7:45 a.m. and complained of abdominal pain. He
then fell back asleep and woke at 12:45 p.m., complaining of abdominal pain. The mother drove
L.A. to the emergency room, but he said he was fine and they turned around to go home. When
they were almost home, L.A. was staring with his eyes deviated to the left and he was stiff and
unresponsive to his mother calling his name and shaking him. He was stiff all over and had a
tonic-clonic movement. His mother called 911. L.A. seized for 25 minutes when EMS came,
and gave him 4.2 mg. of Valium, stopping the seizure. The mother said the past three days, L.A.
had been sleeping a lot. The father also had a fever and headache a week and one-half earlier.
L.A.’s white blood cell count was 30,000. Id. at 4-6.
From December 31, 2010 to February 2, 2011, L.A. was hospitalized at Wolfson
Children’s Hospital. Med. recs. Ex. 2, at 144. The discharge summary states L.A. had
encephalitis of unknown etiology, hyperkinetic movement disorder, expressive aphasia, and
motor ataxia secondary to encephalitis. Dr. Raj D. Sheth, a neurologist, wrote L.A. had possible
autoimmune encephalitis. Id. at 145. During the hospitalization, on January 2, 2011, L.A.
underwent an EEG, which was abnormal. Med. recs. Ex. 18, at 9.
On January 28, 2011, a VAERS report was filled out, stating that L.A. had a viral
syndrome just prior to his encephalitis. Med. recs. Ex. 9, at 1.
On March 14, 2013, L.A. saw Dr. Leon Dure, a neurologist. Med. recs. Ex. 48, at 4. In
recounting L.A.’s history, Dr. Dure writes that after being admitted to his local hospital, L.A.
was found to be suffering from an influenza infection and developed a progressive
encephalopathy, indicative on MRI of bilateral striatal necrosis. Id.
On July 31, 2013, Dr. Harry S. Abram, Jr., L.A.’s pediatric neurologist, wrote to
petitioners’ attorney, stating L.A. had significant neurological disabilities secondary to his
“vaccine-related encephalopathy,” and listing his recommendations for L.A.’s care. Med. recs.
52 at 33.
On September 15, 2013, L.A. saw Dr. Irene A.C. Malaty, a neurologist, who noted what
happened to L.A. was likely an autoimmune or para-infectious event. Med. recs. Ex. 50, at 8.
12

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 13 of 22
TESTIMONY
Magnus Akerstrom, L.A.’s father, testified first and offered a commentary on a 15-
minute DVD, which petitioners showed in the courtroom, depicting L.A. on December 25 and
26, 2010 when he seemed completely healthy.
Dr. Carlo Tornatore testified next for petitioners. He has seen one BSN case in his
career. He explained that BSN is an immune-mediated disease. It fits within the category of
ADEM. The problem comes from the blood, i.e., inflammation starts outside the brain. The
trigger of the inflammation is immune modulation. An infection, which can be viral or bacterial
(such as Mycoplasma pneumoniae), targets the blood-brain barrier. Symptoms occur abruptly,
even within 24-48 hours. Dr. Tornatore believed that L.A.’s test result for IgM for Mycoplasma
pneumoniae was a false positive. L.A. had positive antibodies to striated muscle, which is
associated with myasthenia gravis, but he does not have myasthenia gravis. L.A. had positive
antibodies to thyroid, but he does not have thyroid problems.
Dr. Tornatore believed that FluMist augmented L.A.’s immune system response
through synergy with his pre-vaccinal infectious illness. He testified that influenza A virus is the
most common infection associated with BSN. FluMist contains two attenuated viral strains of
influenza A and one attenuated viral strain of influenza B.
On cross-examination, Dr. Tornatore recognized that L.A. had a systemic illness on
December 28, 2010, consisting of non-specific symptoms of headache, fever, stomachache, and
cough. L.A. had a fever of 101 degrees the morning of December 29, 2010. When his mother
brought him and his brother to the pediatrician in the afternoon, L.A. had a normal temperature
and no symptoms. His neurological symptoms related to BSN occurred just two days later on
December 31, 2010, when he had a seizure, and a head CT scan showed hypodensity in his left
basal ganglia. Dr. Tornatore testified L.A. had a systemic response to FluMist.
The undersigned asked Dr. Tornatore if he believed that but for FluMist, L.A. would not
have had BSN, and he replied in the affirmative. The undersigned asked Dr. Tornatore if he
regarded both the pre-vaccinal infection and FluMist as substantial factors in causing L.A.’s
BSN, and he replied in the affirmative.
Dr. Hayley Gans testified first for respondent. L.A. was a healthy child who, on
December 28, 2010, had an acute febrile illness with non-specific symptoms. L.A. was still
mounting an immune response on December 29, 2010 when he had a fever of 101 degrees in the
morning. She testified that FluMist did not influence his clinical course.
On cross-examination, petitioners’ counsel reminded Dr. Gans that L.A. had received
FluMist on September 9, 2009, followed a month later by an episode of flu. L.A. received
another FluMist in November 2009. During the winter flu season of 2009-2010, there were two
13

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 14 of 22
flu vaccinations, a monovalent one containing H N and a trivalent one containing three flu
1 1
strains.
Dr. Gans admitted that someone receiving FluMist can have as a consequence nasal
congestion, cough, fever, headaches, wheezing, abdominal pain, and fatigue, symptoms L.A. had
after his receipt of FluMist on December 29, 2010. When petitioners’ counsel said the doctors in
the hospital never treated L.A. for Mycoplasma pneumoniae, Dr. Gans replied that by the time
the doctors discovered he had Mycoplasma pneumoniae, treating it would not have done any
good because what L.A. was experiencing was the immune-mediated consequence of the
infection.
Dr. Michael Kohrman testified second for respondent. He has never seen a BSN case.
He said that ADEM (the category within which BSN fits) is a reaction to either a bacterial or
viral infection or to a vaccine. Although wild influenza virus has been associated with BSN,
FluMist has not been so associated in the literature. L.A.’s December 31, 2010 brain CT scan
showing hypodensity was a marker of injury because it showed tissue change. L.A.’s subsequent
brain MRI showed global greater signal changes. Dr. Kohrman said that these sequences take
three days to appear on a brain MRI, which means the process began three to five days before
December 31, 2010.
Dr. Kohrman testified that Mycoplasma pneumoniae was a sufficient and necessary
cause of L.A.’s BSN and that no other cause, i.e., FluMist, was needed for causation. He
considered L.A.’s prolonged somnolence between vaccination and seizure indicative of an
increasing immune-mediated encephalopathy.
There proceeded an extended discussion of the two-day onset interval, which Dr.
Kohrman rejected and Dr. Tornatore accepted as causative. Petitioners submitted into evidence
as Exhibit 63 an article entitled, Acute disseminated encephalomyelitis, by S. Tenembaum, et al.,
68 (Supp. 2) Neur:S23-S36 (2007), which states that ADEM begins within two days to four
weeks after an antigenic challenge. Id. at S23-S24. Moreover, in the fourth attachment to
Exhibit 46, page 328, Goutières and Aicardi mention presenting symptoms at two days in a sub-
group of ADEM. Petitioners also submitted into evidence page 299 from Adverse Effects of
Vaccines. Evidence and Causality, K. Stratton et al., eds., Institute of Medicine (2012), as Ex.
64. That page cites an article by Froissart et al., describing a woman who had vomiting, fever,
and a stiff neck leading to a diagnosis of meningoencephalitis two days after receiving flu
vaccine. The prior year, she had similar symptoms also two days after receiving flu vaccine.
Dr. Steven McGeady testified third for respondent. Dr. McGeady previously submitted,
as part of his reference 5 filed September 24, 2015, pages 293-98 from the same chapter of
Adverse Effects of Vaccines. Evidence and Causality as petitioners’ Exhibit 64, but not
including page 299. He testified that the medical literature does not support vaccine injury in
this case, particularly since it occurred too soon after FluMist. He would pick four to five days
as the optimal onset interval. Dr. McGeady also stated that doctors are unsure of the immune
14

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 15 of 22
mechanisms underlying BSN, although some say it is autoimmune. He has never seen a BSN
case.
The undersigned asked each of respondent’s experts if it was good practice for L.A.’s
pediatrician to give L.A. FluMist the same day as his having a fever of 101 degrees in the
morning. The undersigned stated her understanding that a parent does not even send an ill child
to school until 24 hours have passed without a fever. Dr. Gans had previously testified that the
fever of 101 degrees the morning of December 29, 2010 showed that L.A. was fighting off the
infection he had pre-vaccine. Each of respondent’s experts stated that it was completely
appropriate to vaccinate L.A. the afternoon of December 29, 2010 because it is general pediatric
practice not to miss an opportunity to vaccinate a child because the doctor does not know when
he will see the child again. Moreover, if the child contracts the disease that the vaccine would
prevent, the risks from the disease are far worse than the risk from the vaccination. Dr. Gans
recognized the consensus that a parent does not send a child to school until 24 hours have
elapsed without a fever, but stated that the public policy of avoiding a missed opportunity to
vaccinate was still valid. The undersigned asked each of respondent’s experts if he or she would
be vaccinated if he or she had a cold, and the answer from each of respondent’s experts was in
the affirmative.
At the end of the hearing, the undersigned said that she was leaning toward ruling for
petitioners, relying on the Federal Circuit’s admonition in Althen that, in a close case, the special
masters are to rule for petitioners. See Althen v. Sec’y of HHS, 418 F.3d 1274 (Fed. Cir. 2005).
The undersigned said that if she did rule for petitioners, she thought petitioners should receive
$250,000.00 for L.A.’s past pain and suffering since it has been six years since his injury.
DISCUSSION
To satisfy their burden of proving causation in fact, petitioners must prove by
preponderant evidence: “(1) a medical theory causally connecting the vaccination and the injury;
(2) a logical sequence of cause and effect showing that the vaccination was the reason for the
injury; and (3) a showing of a proximate temporal relationship between vaccination and injury.”
Althen, 418 F.3d at 1278. In Althen, the Federal Circuit quoted its opinion in Grant v. Secretary
of Health and Human Services, 956 F.2d 1144, 1148 (Fed. Cir. 1992):
A persuasive medical theory is demonstrated by “proof of a logical
sequence of cause and effect showing that the vaccination was the
reason for the injury[,]” the logical sequence being supported by
“reputable medical or scientific explanation[,]” i.e., “evidence in
the form of scientific studies or expert medical testimony[.]”
Althen, 418 F.3d at 1278.
15

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 16 of 22
Without more, “evidence showing an absence of other causes does not meet petitioners’
affirmative duty to show actual or legal causation.” Grant, 956 F.2d at 1149. Mere temporal
association is not sufficient to prove causation in fact. Id. at 1148.
Petitioners must show not only that but for FluMist, L.A. would not have had BSN, but
also that FluMist was a substantial factor in causing his BSN. Shyface v. Sec’y of HHS, 165
F.3d 1344, 1352 (Fed. Cir. 1999).
In Capizzano v. Secretary of Health and Human Services, 440 F.3d 1317, 1325 (Fed. Cir.
2006), the Federal Circuit said: “we conclude that requiring either epidemiologic studies,
rechallenge, the presence of pathological markers or genetic disposition, or general acceptance in
the scientific or medical communities to establish a logical sequence of cause and effect is
contrary to what we said in Althen . . . .” Such an approach is inconsistent with the use of
circumstantial evidence. Id. The Federal Circuit stated in Althen, 418 F.3d at 1280, that “the
purpose of the Vaccine Act’s preponderance standard is to allow the finding of causation in a
field bereft of complete and direct proof of how vaccines affect the human body.”
Close calls are to be resolved in favor of petitioners. Capizzano, 1440 F.3d at 1327;
Althen, 418 F.3d at 1280.
“Petitioner need not show that the vaccine was the sole or predominant cause of her
injury,” just that the vaccine was a substantial factor in causing her injury. De Bazan v. Sec’y of
HHS, 539 F.3d, 1347, 1351 (Fed. Cir. 2008).
In essence, the special master is looking for a medical explanation of a logical sequence
of cause and effect (Althen, 418 F.3d at 1278; Grant, 956 F.2d at 1148), and medical probability
rather than certainty (Knudsen v. Sec’y of HHS, 35 F.3d 543, 548-49 (Fed. Cir. 1994)). To the
undersigned, medical probability means biologic credibility rather than specification of an exact
biologic mechanism. As the Federal Circuit stated in Knudsen:
Furthermore, to require identification and proof of specific biological mechanisms
would be inconsistent with the purpose and nature of the vaccine compensation
program. The Vaccine Act does not contemplate full blown tort litigation in the
Court of Federal Claims. The Vaccine Act established a federal “compensation
program” under which awards are to be “made to vaccine-injured persons quickly,
easily, and with certainty and generosity.” House Report 99-908, supra, at 3, 1986
U.S.C.C.A.N. at 6344.
The Court of Federal Claims is therefore not to be seen as a vehicle for ascertaining
precisely how and why DTP and other vaccines sometimes destroy the health and
lives of certain children while safely immunizing most others.
35 F.3d at 549.
16

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 17 of 22
As for epidemiological support for causation, the Federal Circuit in Knudsen, 35 F.3d at
551, ruled for petitioners even when epidemiological evidence directly opposed causation from
DPT vaccine. The case concerned the cause of a baby’s encephalopathy after a vaccination.
Respondent provided evidence that more encephalopathies are caused by viruses than by
vaccines, convincing the special master to rule against petitioners. However, the Federal Circuit
thought the epidemiologic evidence should not bar petitioners from prevailing. Even though
epidemiological evidence supported respondent’s defense in Knudsen that viruses were more
likely to cause encephalopathy than vaccinations, the Federal Circuit held that that fact alone was
not an impediment to recovery of damages. In Knudsen, the Federal Circuit stated:
The bare statistical fact that there are more reported cases of viral
encephalopathies than there are reported cases of DTP
encephalopathies is not evidence that in a particular case an
encephalopathy following a DTP vaccination was in fact caused by
a viral infection present in the child and not caused by the DTP
vaccine.
35 F.3d at 550.
The special masters “are entitled–indeed, expected–to make determinations as to the
reliability of the evidence presented to them and, if appropriate, as to the credibility of the
persons presenting that evidence.” Moberly v. Sec’y of HHS, 592 F.3d 1315, 1325 (Fed. Cir.
2010).
In this case, the undersigned sees the very defenses respondent presented in prior cases
but which the Federal Circuit rejected in ruling for petitioners. In Knudsen, respondent’s expert
espoused a “unity” theory that “the only single thing that could explain all of [the baby’s]
symptoms, encephalitic and non-encephalitic, was a systemic viral infection.” 35 F.3d at 550.
This is very similar to Dr. Kohrman’s testimony that Mycoplasma pneumoniae is a necessary and
sufficient cause of A.L.’s BSN, and no other cause, i.e., FluMist, was necessary. The Federal
Circuit in Knudsen rejected respondent’s unity theory, deciding that the baby’s rhinorrhea was
due to a virus, but her encephalopathy was due to her DPT vaccination. Id.
Respondent also defends based on the lack of epidemiological studies and medical
literature supportive of FluMist playing any role in causing BSN. Moreover, respondent argue
that since doctors do not know the pathological cause of BSN, although it seems to be immune-
mediated, petitioners cannot prove the mechanism of FluMist causing BSN, even in tandem with
a pre-vaccinal infection. In Knudsen, the Federal Circuit stated petitioner does not need
epidemiological support in order to prevail and does not have the burden of proving a specific
biological mechanism. Id. In Althen and Capizzano, the Federal Circuit stated petitioner does
not need to file supportive medical literature in order to prevail.
17

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 18 of 22
A great deal of discussion in this case concerned the fact the FluMist is manufactured so
that it will not replicate outside the nares or nostrils. Therefore, respondent’s experts posited that
it could not cause any harm to the rest of the body. This defense eliminates the idea that FluMist
can lead to systemic symptoms (such as fever, headache, stomachache, cough, stuffy nose). It
also eliminates the idea that FluMist can lead to an immune-mediated response, just as an
infection can. Dr. Gans noted that there was no point in treating L.A.’s infection identified as
Mycoplasma pneumoniae in the hospital because L.A. had moved on to the immune-mediated
phase. The undersigned has ruled in another case dealing with FluMist that it can lead to an
immune misdirection, as petitioners’ expert described. In Agnew v. Secretary of Health and
Human Services, No. 12-551V, 2016 WL 1612853 (Fed. Cl. Spec. Mstr. Mar. 30, 2016), the
undersigned ruled in favor of petitioners based on their expert immunologist Dr. Joseph
Bellanti’s testimony that FluMist led to immune misdirection, causing the boy at issue acute
hepatitis leading to liver failure and a liver transplant. In addition, the Chief Special Master
ruled for petitioner in Day v. Secretary of Health and Human Services, No. 12-551V, 2016 WL
1612853 (Mar. 30, 2016), holding that both human papillomavirus vaccine and FluMist caused
the vaccinee’s neuromyelitis optica (“NMO”) based on Dr. Tornatore’s testimony.
Respondent has been willing to settle cases, obviously less expensive than this one, in
which FluMist was the vaccine at issue. See Lynch v. Sec’y of HHS, No. 12-676V, 2014 WL
2920653 (Fed. Cl. Spec. Mstr. June 2, 2014) (FluMist caused optic neuritis: $180,000); Peterson
v. Sec’y of HHS, No. 10-119V, 2011 WL 6412119 (Fed. Cl. Spec. Mstr. Oct. 28, 2010) (FluMist
followed hours later by left-sided weakness and ataxia: $35,000); Downing v. Sec’y of HHS, No.
09-582V, 2010 WL 3074386 (Fed. Cl. Spec. Mstr. July 13, 2010) (FluMist caused encephalitis:
$70,000). The undersigned notes that the onset interval in Peterson was hours, not days.
Among the decisions involving Shyface decided by the undersigned which she has
discussed with counsel throughout the progression of this case is Herkert, in which the onset
interval was one day. Herkert, No. 97-518V, 2000 WL 141263. In Herkert, the 18-month-old
boy and his family had been experiencing cold-like symptoms. He appeared to be well when he
received DPaT, but then, the evening of the vaccination, he was drowsy. The next day, he had
transverse myelitis (“TM”) at the cortical (neck) section of his spinal cord. Because his palms
were red, the hospital staff attributed the TM to cytomegalovirus (“CMV”), the virus the family
had been fighting. Petitioners’ expert testified that the vaccine modified the child’s immune
system so that it could no longer fight off the CMV. The undersigned held, based on petitioners’
expert’s testimony, that both the CMV and the vaccine were substantial factors in causing the
child’s TM.
The parallels between Herkert and the instant action are significant. L.A. was also
fighting off an infection that his father and younger brother presumably had. He seemed to be
winning the battle, although in the morning of the day he received FluMist, he still had a fever of
101 degrees, which Dr. Gans described as his immune system still fighting the infection. When
L.A. saw his pediatrician in the afternoon, he had no symptoms and no fever. Yet in the next
two days, culminating in his grand mal seizure, his fever returned and his somnolence and other
18

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 19 of 22
symptoms presented themselves. He was never the same again. Dr. Tornatore described the
effect of FluMist on L.A. as synergistic with the underlying infection, be it Mycoplasma
pneumoniae or some other illness, so that he became markedly worse.
Dr. Gans doubted that FluMist could have the synergistic effect that Dr. Tornatore
described because L.A. had received FluMist twice the year before and he was already
vaccinated against the same strains of flu virus in 2010 as he was in 2009. Therefore, Dr. Gans
said the antigens in the 2010 FluMist that L.A. received would not have evoked a strong
response. The undersigned asked her why public health doctors recommend people receive three
hepatitis B vaccinations and two hepatitis A vaccinations if the first vaccination is sufficient for
immunization. Dr. Gans replied that with killed virus vaccines, the immunizing process needs
repetition, but with attenuated live viral vaccines, the immunization process is complete with the
first vaccination, as in MMR vaccine, possibly with a booster needed later on. Beyond the fact
that hepatitis B vaccine is a recombinant vaccine, not a killed-virus vaccine, Dr. Gans’ answer
does not make much sense. It is standard policy to receive either a killed-virus flu vaccine or a
FluMist vaccine annually. If an attenuated live-viral vaccine is sufficient to confer immunity,
then there should be no other FluMist administered unless the viral strains differ from a prior
year’s FluMist components. Therefore, the undersigned finds Dr. Tornatore’s testimony more
credible on this point than Dr. Gans’ testimony.
All three of respondent’s experts emphasized that L.A.’s pediatrician was correct to
administer FluMist the afternoon of December 29, 2010 because of the public health policy of
not missing an opportunity to vaccinate a child. The undersigned does not set public health
policy, but notes that in Nash, another of her decisions that she has repeatedly mentioned to
counsel, a young boy went to the pediatrician with a fever. See Nash, 2002 WL 1906501. The
doctor vaccinated him with whole-cell DPT and his fever became worse, landing him in the
hospital with pneumococcal meningitis. The reason the boy had fever when he went to the
pediatrician was due to his bacterial infection. The undersigned held that both the
pneumococcus and the DPT were substantial factors in causing his pneumococcal meningitis.
The fact that the pediatrician observed the public health policy of not missing an opportunity to
vaccinate is irrelevant to whether or not the vaccination caused the child’s condition.
The undersigned finds that the same is true in the instant action. No doubt, the
pediatrician took the opportunity to vaccinate L.A. since he was there with his younger brother.
The pediatrician thought what he identified was a viral syndrome was resolved since L.A. was
not symptomatic in the office and his temperature was normal. The question of whether the
pediatrician was following sound public health policy has no bearing on whether FluMist had an
effect on L.A. The undersigned finds that FluMist, through its effect on L.A.’s immune system,
brought back the infection he was fighting and it resulted in BSN. The undersigned finds that
both FluMist and the pre-vaccine infection were substantial factors in causing L.A.’s BSN and
that, but for FluMist, L.A. would have successfully fought off the infection and not have
developed BSN, which Dr. Tornatore called a vanishingly rare disease. The medical literature
discussing BSN repeatedly mentions the abrupt nature of the onset of BSN, including some
19

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 20 of 22
individuals who have onset within two days of an immune trigger. After the hearing, respondent
filed an article entitled, Acute Disseminated Encephalomyelitis. An Update, by T. Menge, et al.,
62 Arch Neurol 1673-80 (2005). Ex. I. The authors state the typical latency period between a
febrile illness and the onset of neurological conditions is 7-14 days, but may be longer in a case
of vaccination-associated ADEM. Id. at 1674. This latency period is in contradistinction to the
following articles:
1. Goutières and Aicardi, concerning destructive lesions in the basal ganglia of children,
which respondent filed as Ex. C, Tab 1, and which petitioners filed as the fourth
attachment to Dr. Tornatore’s report (Ex. 46), in which one of the children had
destructive basal ganglia lesions two days after pharyngitis;
2. Goenka, which petitioners filed as the fifth attachment to Ex. 46, in which one boy
had acute necrotizing encephalopathy two days after having pyrexia, diarrhea, and
vomiting;
3. Yuan, concerning Mycoplasma pneumoniae causing BSN, which petitioners filed as
Ex. 57, in which an eight-year-old boy had central nervous system symptoms of
Parkinsonism and dystonia one day after having respiratory symptoms, and a five-
year-old boy had encephalopathy and dystonia two days after having respiratory
symptoms;
4. Tenembaum, concerning ADEM, which petitioners filed as Ex. 63, which states onset
of ADEM occurs from two days to four weeks after an antigenic challenge; and
5. Stratton (ed.), part of a chapter on encephalitis and encephalopathy after influenza
vaccine, from a book entitled Adverse Effects of Vaccines. Evidence and Causality,
which petitioners filed as Ex. 64, in which the editors include a description of an
article about a woman who had vomiting, fever, and a stiff neck, diagnosed as
meningoencephalitis, two days after receiving flu vaccine, similar to her experience
the prior year when she had similar symptoms after receiving flu vaccine.
The undersigned finds no difficulty in ascribing causation in a two-day interval in the
context of immune activation (or synergistic effect) including repeated and prolonged fevers.
Although Dr. Gans opined that L.A.’s onset might be within one day and not two days, it is
difficult to agree with her because systemic symptoms of somnolence, fever, and headache can
occur post-FluMist. As Dr. Tornatore testified, the clearest neurologic sign was L.A.’s seizure
two days post-FluMist.
Respondent’s experts had an additional reason to opine that FluMist played no role in
causing his BSN: none of L.A.’s treating doctors wrote that FluMist was the cause of L.A.’s
BSN. The Federal Circuit in Capizzano emphasized that the special masters are to evaluate
seriously the opinions of the vaccinee’s treating doctors since “treating physicians are likely to
be in the best position to determine whether a logical sequence of cause and effect show[s] that
the vaccination was the reason for the injury.” 440 F.3d at 1326. See also Broekelschen v. Sec’y
of HHS, 618 F.3d 1339, 1347 (Fed. Cir. 2010); Andreu v. Sec’y of HHS, 569 F.3d 1367, 1375
(Fed. Cir. 2009). The reason the Federal Circuit emphasized the opinions of treating doctors in
20

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 21 of 22
Capizzano was that the then-chief special master dismissed petitioner’s allegation that hepatitis B
vaccine caused her rheumatoid arthritis (“RA”) even though four of her treating physicians wrote
in their medical notes that the vaccine did cause her illness. Capizzano, 440 F.3d at 1323. This
was an Althen prong two analysis, i.e., did hepatitis B vaccine cause petitioner’s RA, since the
then-chief special master held that hepatitis B vaccine could cause RA under Althen prong one.
Id. at 1322.
In the instant action, respondent’s experts used the lack of treating doctor opinion that
FluMist caused L.A.’s BSN in an Althen prong one analysis, i.e., FluMist cannot cause or have a
synergistic effect with a pre-vaccine infection to cause BSN. Arguendo, if FluMist cannot cause
BSN or have a synergistic effect with an infection to cause BSN, it did not cause BSN or have a
synergistic effect with an infection to cause BSN in this case. However, the lack of treating
doctor support that FluMist caused L.A.’s BSN is not uniform. In the discharge summary from
Wolfson Children’s Hospital on February 2, 2011, Dr. Raj D. Sheth, a neurologist, said L.A. had
encephalitis of unknown etiology, although he posited a possible autoimmune encephalitis due to
the positive mycoplasma IgM. Med. recs. Ex. 2, at 144, 145. On the same date, Dr. Harry S.
Abram, L.A.’s treating pediatric neurologist, diagnosed L.A. with encephalitis possibly
autoimmune vs. infectious and encephalopathy. Med. recs. Ex. 18, at 22. In 2013, however, Dr.
Abram wrote to petitioners’ attorney that L.A. had significant neurological disabilities secondary
to his “vaccine-related encephalopathy.” Med. recs. Ex. 52, at 33.
The undersigned has seriously evaluated the diagnoses of L.A.’s treating doctors. But
she also recognizes that they were not involved in the litigation of this case and did not read the
expert reports and appended literature, or listen to the experts’ testimony. The Federal Circuit’s
direction in Capizzano for special masters to consider seriously the opinions of the vaccinee’s
treating doctors is consistent with 42 U.S.C. § 300aa-13(b)(1)(A) and (B), directing the special
masters to consider the entire record, including the diagnoses and medical judgments of doctors.
However, the same statutory directive says, “Any such diagnosis, conclusion, judgment, test
result, report, or summary shall not be binding on the special master or court.” Section 300aa-
13(b)(1). Thus, the undersigned concludes that the lack of any treating doctor except Dr. Abram
in 2013 to opine that FluMist either caused L.A.’s BSN or had a synergistic effect on his pre-
vaccine infection to cause L.A.’s BSN is not determinative of the outcome of this case.
Respondent’s counsel was accurate in the beginning of this hearing when he called L.A.’s
parents heroic. L.A. is also heroic. He had a devastating brain injury, which caused serious
damage from which he is slowly, but incompletely, recovering. The undersigned advises
petitioners’ counsel to update the life care plan, which was previously prepared in 2013.
The undersigned finds that petitioners have satisfied the three prongs of Althen:
(1) FluMist, in combination with a co-existing infection, can synergistically affect
the immune system’s ability to fight off the infection and thus result in BSN;
21

Case 1:12-vv-00629-UNJ Document 98 Filed 01/09/17 Page 22 of 22
(2) FluMist in this case had a synergistic effect with L.A.’s pre-existing infection,
resulting in BSN; and
(3) two days is an appropriate interval between FluMist administration and onset
of BSN where the synergy of FluMist and a pre-existing infection causes BSN.
Petitioners have satisfied the requirements for making a prima facie case of causation in
fact.
CONCLUSION
The undersigned finds in favor of entitlement. This case shall proceed in damages.
IT IS SO ORDERED.
December 15, 2016 s/Laura D. Millman
DATE Laura D. Millman
Special Master
22

================================================================================
DOCUMENT 2: USCOURTS-cofc-1_12-vv-00629-2
Date issued/filed: 2019-12-31
Pages: 29
Docket text: PUBLIC DECISION (Originally filed: 12/06/2019) regarding 182 DECISION Stipulation/Proffer Signed by Special Master Daniel T. Horner. (et) Service on parties made.
--------------------------------------------------------------------------------
Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 1 of 29
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 12-629V
Filed: December 6, 2019
UNPUBLISHED
L.A., a minor, by his parents and
Special Master Horner
natural Guardians, MAGNUS and
BRANDI AKERSTROM,
Damages Decision Based on Proffer;
Influenza Vaccine; Seizures;
Petitioners,
Encephalitis; Bilateral Striatal
v.
Necrosis
SECRETARY OF HEALTH AND
HUMAN SERVICES,
Respondent.
Renee Gentry, Esq., The Law Office of Renee Gentry, Washington, DC for petitioner.
Glenn MacLeod, Esq., U.S. Department of Justice, Washington, DC, for respondent.
DECISION AWARDING DAMAGES1
On September 24, 2012, petitioners filed a petition for compensation on behalf of
their minor son, L.A., under the National Vaccine Injury Compensation Program, 42
U.S.C. §300aa-10, et seq.,2 (the “Vaccine Act”). Petitioners alleged that L.A.’s flu mist
vaccine caused his seizures and encephalitis. Petition at 1. The case was assigned to
Special Master Laura Millman. On December 15, 2016, a ruling on entitlement was
issued finding petitioners entitled to compensation for L.A.’s bilateral striatal necrosis.
(ECF No. 97.) On June 5, 2019, following Special Master Millman’s retirement, this case
was assigned to me.
On December 6, 2019, respondent filed a proffer on award of compensation
(“Proffer”) indicating petitioner should be awarded: a lump sum payment of
1 I intend to post this decision on the United States Court of Federal Claims' website. This means the
decision will be available to anyone with access to the internet. In accordance with Vaccine Rule
18(b), petitioner has 14 days to identify and move to redact medical or other information, the disclosure of
which would constitute an unwarranted invasion of privacy. If, upon review, I agree that the identified
material fits within this definition, I will redact such material from public access. Because this unpublished
decision contains a reasoned explanation for the action in this case, I am required to post it on the United
States Court of Federal Claims' website in accordance with the E-Government Act of 2002. 44 U.S.C. §
3501 note (2012) (Federal Management and Promotion of Electronic Government Services).
2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for
ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. §
300aa (2012).

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 2 of 29
$1,352,278.47, representing compensation for lost earnings ($1,047,884.72), pain and
suffering ($250,000), and life care expenses for year one ($54,393.75), payable to
petitioners as guardians/conservators of L.A.; a lump sum payment of $66,794.04,
representing compensation for past unreimbursable expenses, payable to petitioners;
and an amount sufficient to purchase the annuity contract as described in the Proffer.
Proffer at 3. In the Proffer, respondent represented that petitioners agree with the
proffered award. Id. Based on the record as a whole, I find that petitioners are entitled
to an award as stated in the Proffer.
Accordingly, pursuant to the terms stated in the attached Proffer and
accompanying Appendix, I award:
• A lump sum payment of $1,352,278.47 in the form of a check payable to the
court-appointed guardian(s)/conservator(s) of the estate of L.A. for the
benefit of L.A.; and
• A lump sum payment of $66,794.04 in the form of a check payable jointly to
petitioners; and
• An amount sufficient to purchase the annuity contract described in the
attached Proffer at Section II.C.
These amounts represent compensation for all damages that would be available under
§15(a).
The clerk of the court is directed to enter judgment in accordance with this
decision.3
IT IS SO ORDERED.
s/ Daniel T. Horner
Daniel T. Horner
Special Master
3 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by the parties’ joint filing of notice
renouncing the right to seek review.
2

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 3 of 29
IN THE UNITED STATES COURT OF FEDERAL CLAIMS
OFFICE OF SPECIAL MASTERS
__________________________________________
)
L.A., a minor, by his parents and natural )
Guardians, MAGNUS and BRANDI )
AKERSTROM, )
)
Petitioners, )
)
v. ) No. 12-629V
) Special Master Horner
SECRETARY OF THE DEPARTMENT OF )
HEALTH AND HUMAN SERVICES, )
)
Respondent. )
__________________________________________)
RESPONDENT'S PROFFER ON AWARD OF COMPENSATION
In her Ruling on Entitlement issued on December 15, 2016, Special Master Millman
found that a preponderance of the evidence supported petitioner’s claim that the FluMist vaccine
administered to L.A. on December 29, 2010, caused his bilateral striatal necrosis. Respondent
now proffers the following regarding the amount of compensation to be awarded.1
I. Items of Compensation
A. Life Care Items
The respondent engaged life care planner, M. Virginia NeSmith Walton, M.S.N., RN,
FNP, CLCP, and petitioners engaged Nancy J. Bond, CCM, CLCP, to provide an estimation of
L.A.’s future vaccine-injury related needs. For the purposes of this proffer, the term “vaccine
related” is as described in the Special Master’s Ruling on Entitlement. All items of
compensation identified in the life care plan are supported by the evidence, and are illustrated by
1 The parties have no objection to the amount of the proffered award of damages. Assuming the Special
Master issues a damages decision in conformity with this proffer, the parties waive their right to seek review of such
damages decision. However, respondent reserves his right, pursuant to 42 U.S.C. § 300aa-12(e), to seek review of
the Special Master’s December 15, 2016, Ruling on Entitlement.
-1-

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 4 of 29
the chart entitled Appendix A: Items of Compensation for L.A., attached hereto as Tab A.2
Petitioners agree.
B. Lost Future Earnings
The parties agree that based upon the evidence of record, L.A. will not be gainfully
employed in the future. Therefore, respondent proffers that L.A. should be awarded lost future
earnings as provided under the Vaccine Act, 42 U.S.C. § 300aa-15(a)(3)(B). Respondent
proffers that the appropriate award for L.A.'s lost future earnings is $1,047,884.72. Petitioners
agree.
C. Pain and Suffering
Respondent proffers that L.A. should be awarded $250,000.00 in actual pain and
suffering. See 42 U.S.C. § 300aa-15(a)(4). Petitioners agree.
D. Past Unreimbursable Expenses
Evidence supplied by petitioners documents their expenditure of past unreimbursable
expenses related to L.A.'s vaccine-related injury. Respondent proffers that petitioners should be
awarded past unreimbursable expenses in the amount of $66,794.04. Petitioners agree.
II. Form of the Award
The parties recommend that the compensation provided to L.A. should be made through a
combination of lump sum payments and future annuity payments as described below, and request
that the Special Master's decision and the Court's judgment award the following:3
2 The chart at Tab A illustrates the annual benefits provided by the life care plan. The annual benefit years
run from the date of judgment up to the first anniversary of the date of judgment, and every year thereafter up to the
anniversary of the date of judgment.
3 Should L.A. die prior to entry of judgment, the parties reserve the right to move the Court for appropriate
relief. In particular, respondent would oppose any award for future medical expenses, lost future earnings, and
future pain and suffering.
-2-

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 5 of 29
A. A lump sum payment of $1,352,278.47 representing compensation for lost earnings
($1,047,884.72), pain and suffering ($250,000.00), and life care expenses for Year One
($54,393.75), in the form of a check payable to petitioners as guardian(s)/conservator(s) of L.A.,
for the benefit of L.A. No payments shall be made until petitioners provide respondent with
documentation establishing that they have been appointed as the guardian(s)/conservator(s) of
L.A.'s estate. If petitioners are not authorized by a court of competent jurisdiction to serve as
guardian(s)/conservator(s) of the estate of L.A., any such payment shall be made to the party or
parties appointed by a court of competent jurisdiction to serve as guardian(s)/conservator(s) of
the estate of L.A. upon submission of written documentation of such appointment to the
Secretary.
B. A lump sum payment of $66,794.04, representing compensation for past
unreimbursable expenses, in the form of a check payable to petitioners, Magnus and Brandi
Akerstrom.
C. An amount sufficient to purchase the annuity contract,4 subject to the conditions
described below, that will provide payments for the life care items contained in the life care plan,
as illustrated by the chart at Tab A attached hereto, paid to the life insurance company5 from
4 In respondent’s discretion, respondent may purchase one or more annuity contracts from one or more life
insurance companies.
5 The Life Insurance Company must have a minimum of $250,000,000 capital and surplus, exclusive of
any mandatory security valuation reserve. The Life Insurance Company must have one of the following ratings
from two of the following rating organizations:
a. L.A. Best Company: A++, A+, A+g, A+p, A+r, or A+s;
b. Moody's Investor Service Claims Paying Rating: Aa3, Aa2, Aa1, or Aaa;
c. Standard and Poor's Corporation Insurer Claims-Paying Ability Rating: AA-, AA, AA+, or
AAA;
d. Fitch Credit Rating Company, Insurance Company Claims Paying Ability Rating: AA-, AA,
AA+, or AAA.
-3-

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 6 of 29
which the annuity will be purchased.6 Compensation for Year Two (beginning on the first
anniversary of the date of judgment) and all subsequent years shall be provided through
respondent's purchase of an annuity, which annuity shall make payments directly to petitioners
only so long as L.A. is alive at the time a particular payment is due. At the Secretary's sole
discretion, the periodic payments may be provided to petitioners in monthly, quarterly, annual or
other installments. The "annual amounts" set forth in the chart at Tab A describe only the total
yearly sum to be paid to petitioners and do not require that the payment be made in one annual
installment.
1. Growth Rate
Respondent proffers that a four percent (4%) growth rate should be applied to all non-
medical life care items, and a five percent (5%) growth rate should be applied to all medical life
care items. Thus, the benefits illustrated in the chart at Tab A that are to be paid through annuity
payments should grow as follows: four percent (4%) compounded annually from the date of
judgment for non-medical items, and five percent (5%) compounded annually from the date of
judgment for medical items. Petitioners agree.
2. Life-Contingent Annuity
The petitioners will continue to receive the annuity payments from the Life Insurance
Company only so long as L.A. is alive at the time that a particular payment is due. Written
notice shall be provided to the Secretary of Health and Human Services and the Life Insurance
Company within twenty (20) days of L.A.’s death.
3. Guardianship
6 Petitioners authorize the disclosure of certain documents filed by the petitioners in this case consistent
with the Privacy Act and the routine uses described in the National Vaccine Injury Compensation Program System
of Records, No. 09-15-0056.
-4-

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 7 of 29
No payments shall be made until petitioners provide respondent with documentation
establishing that they have been appointed as the guardian(s)/conservator(s) of L.A.’s estate. If
petitioners are not authorized by a court of competent jurisdiction to serve as
guardian(s)/conservator(s) of the estate of L.A., any such payment shall be made to the party or
parties appointed by a court of competent jurisdiction to serve as guardian(s)/conservator(s) of
the estate of L.A. upon submission of written documentation of such appointment to the
Secretary.
III. Summary of Recommended Payments Following Judgment
A. Lump Sum paid to the court-appointed guardian(s)/
conservator(s) of the estate of L.A. for the benefit of L.A.: $1,352,278.47
B. Past unreimbursable expenses payable to petitioners: $ 66,794.04
C. An amount sufficient to purchase the annuity contract described
above in section II. C.
Respectfully submitted,
JOSEPH H. HUNT
Assistant Attorney General
C. SALVATORE D’ALESSIO
Acting Director
Torts Branch, Civil Division
CATHARINE E. REEVES
Deputy Director
Torts Branch, Civil Division
HEATHER L. PEARLMAN
Assistant Director
Torts Branch, Civil Division
-5-

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 8 of 29
/s/Glenn A. MacLeod
GLENN A. MACLEOD
Senior Trial Counsel
Torts Branch, Civil Division
U. S. Department of Justice
P.O. Box l46, Benjamin Franklin Station
Washington, D.C. 20044-0146
Direct dial: (202) 616-4122
Dated: December 6, 2019
-6-

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 9 of 29
Appendix A: Items of Compensation for L.A. Page 1 of 21
Lump Sum
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Years 7-8 Year 9
2019 2020 2021 2022 2023 2024 2025-2026 2027
Insurance MOP 5% 6,000.00 6,000.00 6,000.00 6,000.00 6,000.00 6,000.00 6,000.00 6,000.00
Insurance Premium 5% M
Medicare Part B Premium 5% M
Medicare Part B Deductible 5%
Medigap F 5% M
Medicare Part D 5% M
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
PM&R 5% *
Mileage: PM&R 4% 12.00 12.00 12.00 12.00 12.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 6.40 6.40 6.40 6.40 6.40 3.20 3.20 3.20
Neuropsych Eval 4% 1,500.00 1,500.00 1,500.00
Mileage: Neuropsych Eval 4% 3.20 3.20 3.20
EEG 5% *
Mileage: EEG 4% 3.20 3.20 3.20
MRI of Brain 5% *
Mileage: MRI 4% 3.20
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4% 13.20
Counseling 4% * M 7,200.00 2,700.00 2,700.00 2,700.00 2,700.00
Mileage: Counseling 4% 259.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 4,320.00 3,240.00 3,240.00 3,240.00 3,240.00 3,240.00 3,240.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 10 of 29
Appendix A: Items of Compensation for L.A. Page 2 of 21
Lump Sum
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Years 7-8 Year 9
2019 2020 2021 2022 2023 2024 2025-2026 2027
PT Eval 4% *
PT 4% *
Mileage: PT 4% 288.00 288.00 288.00 288.00 288.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 288.00 288.00 288.00 288.00 288.00 72.00 72.00 72.00
Therapeutic Recreation 4% M 1,200.00 1,200.00 1,200.00 1,200.00 1,200.00
Driving Eval/ Training 4% 700.00
Tutoring 4% M 8,316.00 8,316.00 8,316.00 8,316.00 8,316.00
Shower Transfer Bench 4% 292.59 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 300.00 150.00 150.00
EMS 4% *
Electrodes 4% 32.50 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 330.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4% 1,400.00 500.00 500.00 500.00 500.00 500.00 500.00 500.00
Personal Emergency Response
System 4% M 371.40
Scooter 4% 1,999.00
Scooter Maint 4% 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 12,960.00 12,960.00 12,960.00 12,960.00 12,960.00 13,104.00 13,104.00 13,104.00
Ancillary Services 4% M
Ancillary Services 4% M
Home Mods 4% 9,500.00
Braun Seating 4% 10,000.00
Scooter Lift 4% 1,360.00
Steering Knob 4% 66.00 11.00 11.00 11.00
Lost Future Earnings 1,047,884.72
Pain and Suffering 250,000.00
Past Unreimbursable Expenses 66,794.04
Annual Totals 1,419,072.51 36,252.08 37,761.68 36,252.08 52,258.48 24,424.88 24,274.88 24,106.28

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 11 of 29
Appendix A: Items of Compensation for L.A. Page 3 of 21
Lump Sum
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Years 7-8 Year 9
2019 2020 2021 2022 2023 2024 2025-2026 2027
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 12 of 29
Appendix A: Items of Compensation for L.A. Page 4 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Year 16 Year 17
2028 2029 2030 2031 2032 2033 2034 2035
Insurance MOP 5% 6,000.00 6,000.00 6,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00
Insurance Premium 5% M 6,433.80 6,584.52 6,829.56 7,030.68 7,131.12
Medicare Part B Premium 5% M
Medicare Part B Deductible 5%
Medigap F 5% M
Medicare Part D 5% M
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 6.40 6.40 3.20 3.20 3.20 3.20 3.20 3.20
PM&R 5% *
Mileage: PM&R 4% 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
Neuropsych Eval 4%
Mileage: Neuropsych Eval 4%
EEG 5% *
Mileage: EEG 4%
MRI of Brain 5% *
Mileage: MRI 4%
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4%
Counseling 4% * M
Mileage: Counseling 4% 97.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 13 of 29
Appendix A: Items of Compensation for L.A. Page 5 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Year 16 Year 17
2028 2029 2030 2031 2032 2033 2034 2035
PT Eval 4% *
PT 4% *
Mileage: PT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
Therapeutic Recreation 4% M
Driving Eval/ Training 4%
Tutoring 4% M
Shower Transfer Bench 4% 48.77 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 150.00 150.00 150.00 150.00 150.00 150.00 150.00 150.00
EMS 4% *
Electrodes 4% 16.25 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 110.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4% 500.00
Personal Emergency Response
System 4% M 371.40 371.40 371.40 371.40 371.40 371.40 371.40 371.40
Scooter 4% 1,999.00 1,999.00
Scooter Maint 4% 375.00 375.00 375.00 375.00 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00
Ancillary Services 4% M 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00
Ancillary Services 4% M 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28
Home Mods 4% 9,500.00
Braun Seating 4% 10,000.00 10,000.00
Scooter Lift 4% 1,360.00 1,360.00
Steering Knob 4% 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 33,829.56 39,970.56 39,467.36 32,401.16 32,551.88 36,155.92 32,998.04 43,098.48

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 14 of 29
Appendix A: Items of Compensation for L.A. Page 6 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Year 16 Year 17
2028 2029 2030 2031 2032 2033 2034 2035
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 15 of 29
Appendix A: Items of Compensation for L.A. Page 7 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 18 Year 19 Year 20 Year 21 Year 22 Year 23 Year 24 Year 25
2036 2037 2038 2039 2040 2041 2042 2043
Insurance MOP 5% 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00
Insurance Premium 5% M 7,281.96 7,432.80 7,527.00 7,627.56 7,677.72 7,728.00 7,778.28 7,828.56
Medicare Part B Premium 5% M
Medicare Part B Deductible 5%
Medigap F 5% M
Medicare Part D 5% M
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
PM&R 5% *
Mileage: PM&R 4% 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
Neuropsych Eval 4%
Mileage: Neuropsych Eval 4%
EEG 5% *
Mileage: EEG 4%
MRI of Brain 5% *
Mileage: MRI 4%
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4%
Counseling 4% * M
Mileage: Counseling 4% 97.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 16 of 29
Appendix A: Items of Compensation for L.A. Page 8 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 18 Year 19 Year 20 Year 21 Year 22 Year 23 Year 24 Year 25
2036 2037 2038 2039 2040 2041 2042 2043
PT Eval 4% *
PT 4% *
Mileage: PT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
Therapeutic Recreation 4% M
Driving Eval/ Training 4%
Tutoring 4% M
Shower Transfer Bench 4% 48.77 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 150.00 150.00 150.00 150.00 150.00 150.00 150.00 150.00
EMS 4% *
Electrodes 4% 16.25 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 110.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4%
Personal Emergency Response
System 4% M 371.40 371.40 371.40 371.40 371.40 371.40 371.40 371.40
Scooter 4% 1,999.00 399.80 399.80 399.80 399.80 399.80 399.80
Scooter Maint 4% 375.00 375.00 375.00 375.00 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00
Ancillary Services 4% M 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00
Ancillary Services 4% M 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28
Home Mods 4%
Braun Seating 4% 10,000.00 1,666.67 1,666.67
Scooter Lift 4% 1,360.00 272.00 272.00 272.00 272.00 272.00
Steering Knob 4% 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 33,249.32 35,399.16 35,254.16 34,266.72 34,316.88 44,367.16 36,084.11 36,134.39

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 17 of 29
Appendix A: Items of Compensation for L.A. Page 9 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 18 Year 19 Year 20 Year 21 Year 22 Year 23 Year 24 Year 25
2036 2037 2038 2039 2040 2041 2042 2043
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 18 of 29
Appendix A: Items of Compensation for L.A. Page 10 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 26 Year 27 Year 28 Year 29 Year 30 Year 31 Year 32 Year 33
2044 2045 2046 2047 2048 2049 2050 2051
Insurance MOP 5% 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00
Insurance Premium 5% M 7,929.12 8,029.68 8,180.40 8,324.88 8,526.00 8,777.28 9,072.60 9,424.44
Medicare Part B Premium 5% M
Medicare Part B Deductible 5%
Medigap F 5% M
Medicare Part D 5% M
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
PM&R 5% *
Mileage: PM&R 4% 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
Neuropsych Eval 4%
Mileage: Neuropsych Eval 4%
EEG 5% *
Mileage: EEG 4%
MRI of Brain 5% *
Mileage: MRI 4%
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4%
Counseling 4% * M
Mileage: Counseling 4% 97.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 19 of 29
Appendix A: Items of Compensation for L.A. Page 11 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 26 Year 27 Year 28 Year 29 Year 30 Year 31 Year 32 Year 33
2044 2045 2046 2047 2048 2049 2050 2051
PT Eval 4% *
PT 4% *
Mileage: PT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
Therapeutic Recreation 4% M
Driving Eval/ Training 4%
Tutoring 4% M
Shower Transfer Bench 4% 48.77 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 150.00 150.00 150.00 150.00 150.00 150.00 150.00 150.00
EMS 4% *
Electrodes 4% 16.25 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 110.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4%
Personal Emergency Response
System 4% M 371.40 371.40 371.40 371.40 371.40 371.40 371.40 371.40
Scooter 4% 399.80 399.80 399.80 399.80 399.80 399.80 399.80 399.80
Scooter Maint 4% 375.00 375.00 375.00 375.00 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00 13,104.00
Ancillary Services 4% M 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00
Ancillary Services 4% M 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28
Home Mods 4%
Braun Seating 4% 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67
Scooter Lift 4% 272.00 272.00 272.00 272.00 272.00 272.00 272.00 272.00
Steering Knob 4% 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 36,234.95 36,335.51 36,486.23 36,630.71 36,831.83 37,083.11 37,378.43 37,730.27

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 20 of 29
Appendix A: Items of Compensation for L.A. Page 12 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 26 Year 27 Year 28 Year 29 Year 30 Year 31 Year 32 Year 33
2044 2045 2046 2047 2048 2049 2050 2051
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 21 of 29
Appendix A: Items of Compensation for L.A. Page 13 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 34 Year 35 Year 36 Year 37 Year 38 Year 39 Year 40 Year 41
2052 2053 2054 2055 2056 2057 2058 2059
Insurance MOP 5% 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00
Insurance Premium 5% M 9,820.32 10,272.60 10,718.76 11,221.32 11,717.76 12,264.36 12,817.20 13,414.08
Medicare Part B Premium 5% M
Medicare Part B Deductible 5%
Medigap F 5% M
Medicare Part D 5% M
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
PM&R 5% *
Mileage: PM&R 4% 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
Neuropsych Eval 4%
Mileage: Neuropsych Eval 4%
EEG 5% *
Mileage: EEG 4%
MRI of Brain 5% *
Mileage: MRI 4%
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4%
Counseling 4% * M
Mileage: Counseling 4% 97.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 22 of 29
Appendix A: Items of Compensation for L.A. Page 14 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 34 Year 35 Year 36 Year 37 Year 38 Year 39 Year 40 Year 41
2052 2053 2054 2055 2056 2057 2058 2059
PT Eval 4% *
PT 4% *
Mileage: PT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
Therapeutic Recreation 4% M
Driving Eval/ Training 4%
Tutoring 4% M
Shower Transfer Bench 4% 48.77 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 150.00 150.00 150.00 150.00 150.00 150.00 150.00 150.00
EMS 4% *
Electrodes 4% 16.25 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 110.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4%
Personal Emergency Response
System 4% M 371.40 371.40 371.40 371.40 371.40 371.40 371.40 371.40
Scooter 4% 399.80 399.80 399.80 399.80 399.80 399.80 399.80 399.80
Scooter Maint 4% 375.00 375.00 375.00 375.00 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 13,104.00 13,104.00 13,104.00 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00
Ancillary Services 4% M 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00
Ancillary Services 4% M 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28
Home Mods 4% 12,000.00
Braun Seating 4% 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67
Scooter Lift 4% 272.00 272.00 272.00 272.00 272.00 272.00 272.00 272.00
Steering Knob 4% 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 38,126.15 38,578.43 39,024.59 71,273.15 59,769.59 60,316.19 60,869.03 61,465.91

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 23 of 29
Appendix A: Items of Compensation for L.A. Page 15 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 34 Year 35 Year 36 Year 37 Year 38 Year 39 Year 40 Year 41
2052 2053 2054 2055 2056 2057 2058 2059
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 24 of 29
Appendix A: Items of Compensation for L.A. Page 16 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 42 Year 43 Year 44 Year 45 Year 46 Year 47 Year 48 Year 49
2060 2061 2062 2063 2064 2065 2066 2067
Insurance MOP 5% 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00 2,000.00
Insurance Premium 5% M 14,010.96 14,658.12 15,311.52 16,008.96 16,354.56 17,052.00 17,655.12 18,051.00
Medicare Part B Premium 5% M
Medicare Part B Deductible 5%
Medigap F 5% M
Medicare Part D 5% M
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
PM&R 5% *
Mileage: PM&R 4% 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
Neuropsych Eval 4%
Mileage: Neuropsych Eval 4%
EEG 5% *
Mileage: EEG 4%
MRI of Brain 5% *
Mileage: MRI 4%
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4%
Counseling 4% * M
Mileage: Counseling 4% 97.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 25 of 29
Appendix A: Items of Compensation for L.A. Page 17 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 42 Year 43 Year 44 Year 45 Year 46 Year 47 Year 48 Year 49
2060 2061 2062 2063 2064 2065 2066 2067
PT Eval 4% *
PT 4% *
Mileage: PT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
Therapeutic Recreation 4% M
Driving Eval/ Training 4%
Tutoring 4% M
Shower Transfer Bench 4% 48.77 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 150.00 150.00 150.00 150.00 150.00 150.00 150.00 150.00
EMS 4% *
Electrodes 4% 16.25 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 110.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4%
Personal Emergency Response
System 4% M 371.40 371.40 371.40 371.40 371.40 371.40 371.40 371.40
Scooter 4% 399.80 399.80 399.80 399.80 399.80 399.80 399.80 399.80
Scooter Maint 4% 375.00 375.00 375.00 375.00 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00
Ancillary Services 4% M 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00
Ancillary Services 4% M 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28
Home Mods 4%
Braun Seating 4% 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67
Scooter Lift 4% 272.00 272.00 272.00 272.00 272.00 272.00 272.00 272.00
Steering Knob 4% 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 62,062.79 62,709.95 63,363.35 64,060.79 64,406.39 65,103.83 65,706.95 66,102.83

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 26 of 29
Appendix A: Items of Compensation for L.A. Page 18 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 42 Year 43 Year 44 Year 45 Year 46 Year 47 Year 48 Year 49
2060 2061 2062 2063 2064 2065 2066 2067
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 27 of 29
Appendix A: Items of Compensation for L.A. Page 19 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 50 Year 51 Years 52-53 Year 54 Year 55 Year 56 Year 57 Years 58-Life
2068 2069 2070-2071 2072 2073 2074 2075 2076-Life
Insurance MOP 5% 2,000.00 2,000.00
Insurance Premium 5% M 18,547.32 18,848.88
Medicare Part B Premium 5% M 1,626.00 1,626.00 1,626.00 1,626.00 1,626.00 1,626.00
Medicare Part B Deductible 5% 185.00 185.00 185.00 185.00 185.00 185.00
Medigap F 5% M 2,343.12 2,421.36 2,517.12 2,609.88 2,705.64 3,381.24
Medicare Part D 5% M 390.00 390.00 390.00 390.00 390.00 390.00
PCP 5% *
Mileage: PCP 4% 6.40 6.40 6.40 6.40 6.40 6.40 6.40 6.40
Neurology 5% *
Mileage: Neurology 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
PM&R 5% *
Mileage: PM&R 4% 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00
Orthopedist 5% *
Mileage: Orthopedist 4% 3.20 3.20 3.20 3.20 3.20 3.20 3.20 3.20
Neuropsych Eval 4%
Mileage: Neuropsych Eval 4%
EEG 5% *
Mileage: EEG 4%
MRI of Brain 5% *
Mileage: MRI 4%
Deep Brain Stimulation 5% *
Podiatry 4% 120.00 120.00 120.00 120.00 120.00 120.00 120.00 120.00
Neuro-Opthal Eval 5% *
Mileage: NeuroOpthal Eval 4%
Counseling 4% * M
Mileage: Counseling 4% 97.20 97.20 97.20 97.20 97.20 97.20 97.20 97.20
Care Mngt 4% M 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00 2,700.00
Trileptal 5% *
Diastat 5% *
Periactin 5% *
Carnation Instant Breakfast 4% 176.66 176.66 176.66 176.66 176.66 176.66 176.66 176.66
Anxietry Rx 5% *

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 28 of 29
Appendix A: Items of Compensation for L.A. Page 20 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 50 Year 51 Years 52-53 Year 54 Year 55 Year 56 Year 57 Years 58-Life
2068 2069 2070-2071 2072 2073 2074 2075 2076-Life
PT Eval 4% *
PT 4% *
Mileage: PT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
OT Eval 4% *
OT 4% *
Mileage: OT 4% 72.00 72.00 72.00 72.00 72.00 72.00 72.00 72.00
Therapeutic Recreation 4% M
Driving Eval/ Training 4%
Tutoring 4% M
Shower Transfer Bench 4% 48.77 48.77 48.77 48.77 48.77 48.77 48.77 48.77
Orthotic 4% 150.00 150.00 150.00 150.00 150.00 150.00 150.00 150.00
EMS 4% *
Electrodes 4% 16.25 16.25 16.25 16.25 16.25 16.25 16.25 16.25
Adaptive Devices 4% 160.00 160.00 160.00 160.00 160.00 160.00 160.00 160.00
Voice Activated Computer
Program & Hardware 4% 110.00 110.00 110.00 110.00 110.00 110.00 110.00 110.00
Text to Speech Software 4%
Personal Emergency Response
System 4% M 371.40 371.40 371.40 371.40 371.40 371.40 371.40 371.40
Scooter 4% 399.80 399.80 399.80 399.80 399.80 399.80 399.80 399.80
Scooter Maint 4% 375.00 375.00 375.00 375.00 375.00 375.00 375.00 375.00
Companion/Respite/Personal
Care 4% M 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00 32,850.00 63,236.25
Ancillary Services 4% M 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00 2,925.00
Ancillary Services 4% M 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28 3,439.28
Home Mods 4%
Braun Seating 4% 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67 1,666.67
Scooter Lift 4% 272.00 272.00 272.00 272.00 272.00 272.00 272.00 272.00
Steering Knob 4% 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00
Lost Future Earnings
Pain and Suffering
Past Unreimbursable Expenses
Annual Totals 66,599.15 66,900.71 50,595.95 50,674.19 50,769.95 50,862.71 50,958.47 82,020.32

Case 1:12-vv-00629-UNJ Document 184 Filed 12/31/19 Page 29 of 29
Appendix A: Items of Compensation for L.A. Page 21 of 21
Compensation Compensation Compensation Compensation Compensation Compensation Compensation Compensation
ITEMS OF COMPENSATION G.R. * M Year 50 Year 51 Years 52-53 Year 54 Year 55 Year 56 Year 57 Years 58-Life
2068 2069 2070-2071 2072 2073 2074 2075 2076-Life
Note: Compensation Year 1 consists of the 12 month period following the date of judgment.
Compensation Year 2 consists of the 12 month period commencing on the first anniversary of the date of judgment.
As soon as practicable after entry of judgment, respondent shall make the following payment to the court-appointed guardian(s)/
conservators(s) of the estate of Luke Akerstrom for the benefit of Luke Akerstrom for lost future earnings ($1,047,884.72),
pain and suffering ($250,000.00), and Yr 1 life care expenses ($54,393.75): $1,352,278.47.
As soon as practicable after entry of judgment, respondent shall make the following payment to petitioners, Magnus and
Brandi Akerstrom, for past un-reimbursable expenses: $66,794.04.
Annual amounts payable through an annuity for future Compensation Years follow the anniversary of the date of judgment.
Items denoted with an asterisk (*) covered by health insurance and/or Medicare.
Items denoted with an "M" payable in 12 monthly installments at the discretion of respondent.